To explore the potential therapeutic role of GBM inflammation, we investigated the therapeutic effect of Azeliragon (AZG, TTP488, PF-04494700), a small molecule in clinical trials that inhibits the binding of ligands, including S100 proteins, to the receptor for advanced glycation end products (RAGE). Here, AGER is linked to glioblastoma.